(Futuximab + modotuximab) is under clinical development by Symphogen and currently in Phase III for Metastatic Colorectal Cancer. According to GlobalData, Phase III drugs for Metastatic Colorectal Cancer have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Futuximab + modotuximab)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Futuximab + modotuximab) overview

A fixed-dose combination of futuximab and modotuximab (Sym-004) is under development for the treatment of recurrent glioblastoma and metastatic colorectal cancer. The drug candidate is administered as an intravenous infusion. Futuximab and modotuximab are synergistic full-length anti-EGFR antibodies, which bind to two separate non-overlapping epitopes on epidermal growth factor receptor (EGFR). The drug candidate is developed based on symplex, symselect and sympress technologies. It was also under development for the treatment of squamous non-small cell lung cancer and squamous cell carcinoma of head and neck cancer, metastatic colorectal cancer (as a second line therapy), advanced solid tumors including esophageal squamous cell carcinoma.

Symphogen overview

Symphogen is a biopharmaceutical company that specializes in the field of recombinant antibody mixtures for therapeutic use in cancer. The company focuses on developing superior monoclonal antibody (mAb) mixture therapeutics. The product pipeline provides novel approaches to a wide range of cancer types including metastatic colorectal cancer (mCRC), solid tumor malignancies, and lung cancer. It has collaborations for the development of antibody therapeutics in immuno-oncology with the Shire and infectious disease area with Genentech. The company has offices in Denmark and New Jersey, the US. Symphogen is headquartered in Ballerup, Denmark.

For a complete picture of (Futuximab + modotuximab)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.